| Systematic (IUPAC) name | |
|---|---|
| 2-phenyl-4-(2-piperidin-4-ylethyl)quinoline | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 77472-98-1 |
| ATC code | None |
| PubChem | CID 71219 |
| ChemSpider | 64354 |
| UNII | J3S205V4I2 |
| Chemical data | |
| Formula | C22H24N2 |
| Mol. mass | 316.439 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Pipequaline (PK-8165) is an anxiolytic drug with a novel chemical structure that is not closely related to other drugs of this type. It has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and very little sedative, amnestic or anticonvulsant effects, and so is classified as a nonbenzodiazepine anxiolytic.[1][2][3]
Pipequaline acts as a non-selective GABAA receptor partial agonist.[4][5][6] While its profile of anxiolytic effects without sedation would appear to have potential medical applications, pipequaline has never been developed for medical use and is currently only used in scientific research.
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)